The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

@article{Satsangi2006TheMC,
  title={The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications},
  author={Jack Satsangi and Mark S. Silverberg and S Vermeire and J-F Colombel},
  journal={Gut},
  year={2006},
  volume={55},
  pages={749 - 753}
}
In recent years, investigators have readdressed the complex issues involved in the classification of inflammatory bowel diseases. In 2003, a Working Party of investigators with an interest in the issues involved in disease subclassification was formed with the aim of summarising recent developments in disease classification and establishing an integrated clinical, molecular, and serological classification of inflammatory bowel disease. The results of the Working Party were reported at the 2005… Expand
Consensus guidelines for the management of inflammatory bowel disease.
This is the first Brazilian Consensus on inflammatory bowel disease, carried out by the Brazilian Study Group of Inflammatory Bowel Disease, and discusses the treatment of Crohn's disease andExpand
Crohn's disease - historical revue of classifications.
Summary: Crohn’s disease is a heterogeneous, chronic, granulomatous inflammation, localized in the gastrointestinal tract, predominantly in the terminal ileum and the proximal part of the colon. TheExpand
Guidelines for the management of inflammatory bowel disease in adults
TLDR
The present document is intended primarily for the use of clinicians in the United Kingdom, and serves to replace the previous BSG guidelines in IBD, while complementing recent consensus statements published by the European Crohn's and Colitis Organisation (ECCO). Expand
Inflammatory bowel diseases: the paediatric gastroenterologist's perspective
TLDR
In children presenting with symptoms compatible with IBD, gut exploration by US may identify those who will benefit from more invasive explorations including endoscopy, and new imaging methods are useful during patient follow-up for assessing disease activity and for the diagnosis of complications. Expand
First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus
TLDR
This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence- and expert opinion-based recommendations about diagnosis, treatment, and management of main complications of ulcerative colitis and Crohn’s disease. Expand
The histopathological mimics of inflammatory bowel disease: a critical appraisal
TLDR
This review presents an up-to-date evaluation of the histopathological mimics of IBD and suggests that several diseases frequently mimic the histological changes seen in IBD. Expand
The challenges of stratifying patients for trials in inflammatory bowel disease.
TLDR
The opportunities and the challenges of identifying clinical, immunological, biochemical or genetic biomarkers to target immunotherapy to patients more likely to respond in inflammatory bowel disease are identified and highlighted. Expand
Scoring systems in inflammatory bowel disease
TLDR
Clinically based IBD classification systems can provide the basis for the eventual correlation between the underlying genotype with clinical expression of disease and lead to better characterization of disease subtypes and, hopefully, customized treatment regimens. Expand
Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools
TLDR
This study focuses and expands on areas that are not clearly delineated in current guidelines, including the role of prognostication, to determine patient treatment paradigms and the opportunity for a more individualized approach that can inform the selection of immunosuppressant or biologic therapy. Expand
Clinical assessment of inflammatory bowel disease activity: a critical overview
TLDR
This review focuses on the clinical aspects of IBD throughout the years and discusses the most recent and future concepts in IBD diagnosis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
TLDR
The introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work. Expand
A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998
TLDR
The aim of this international Working Party was to develop a simple classification of Crohn's disease based on objective variables, and the allocation of patients to these 24 subgroups proved feasible and resulted in specific disease clusters. Expand
The value of serologic markers in indeterminate colitis: a prospective follow-up study.
TLDR
Evaluated the value of anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) to increase diagnostic accuracy in categorizing IC and results so far show that ASCA+/ pANCA- predicts CD in 80% of patients with IC and ASCA-/pANca+ predicts UC in 63.6%. Expand
Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'.
  • A. Price
  • Medicine
  • Journal of clinical pathology
  • 1978
TLDR
Case of colitis indeterminate form a small distinctive group in the spectrum of inflammatory bowel disease which is characterised by a common pattern of pathology that presents a diagnostic dilemma. Expand
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease.
TLDR
Variation in this gene contributes to the occurrence of fibrostenotic CD of the small bowel, and a genotype/phenotype correlation in CD patients and NOD2 variants is suggested. Expand
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease
TLDR
Location of Crohn's disease, as defined by the Vienna classification, is a relatively stable phenotype which seems suitable for phenotype-genotype analyses and cannot be used in phenotype- genotype analyses. Expand
Mutations in NOD 2 Are Associated With Fibrostenosing Disease in Patients With Crohn ’ s Disease
MARIA T. ABREU,* KENT D. TAYLOR,‡ YING–CHAO LIN,‡ TIEU HANG,‡ JOANNE GAIENNIE,* CAROL J. LANDERS,* ERIC A. VASILIAUSKAS,* LORI Y. KAM,* MICHA ROJANY,* KONSTANTINOS A. PAPADAKIS,* JEROME I. ROTTER,‡Expand
The molecular classification of the clinical manifestations of Crohn's disease.
TLDR
It is confirmed that alleles on specific long-range HLA haplotypes determine overall susceptibility and novel genetic associations with susceptibility, location, and behavior of Crohn's disease are described. Expand
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics
TLDR
By taking into account the magnitude of the host immune response, Crohn's disease can now be stratified on an immunological basis into more homogeneous clinically distinct subgroups, characterised by greater uniformity among anatomical distribution of disease and disease behaviour. Expand
Course of ulcerative colitis: analysis of changes in disease activity over years.
TLDR
About half of patients with UC will be in remission at any time, although 90% have an intermittent course, and relapses are unpredictable except that disease activity in foregoing years indicates with 70%-80% probability that the disease will continue the following year. Expand
...
1
2
3
...